Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Kissei Pharmaceutical Co ( (JP:4547) ).
Kissei Pharmaceutical Co reported a 7.9% year-over-year increase in net sales for the first half of fiscal 2025, driven by growth in both its pharmaceutical and other business segments. Despite a net operating loss, the company saw a significant rise in profits attributable to owners due to extraordinary income from the sale of investment securities. The company has increased its R&D expenses substantially, focusing on the development of treatments for thyroid eye disease and advancing its pipeline. Licensing agreements in Canada and Taiwan, as well as a product launch in South Korea, have bolstered its international presence.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4473.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co is a company operating in the pharmaceutical industry, focusing on the development and sale of pharmaceutical products. The company is involved in both domestic and international markets, with a particular emphasis on treatments for thyroid eye disease and uterine fibroids. It has been actively engaging in licensing agreements to expand its market reach.
Average Trading Volume: 62,590
Technical Sentiment Signal: Buy
Current Market Cap: Yen164.4B
For a thorough assessment of 4547 stock, go to TipRanks’ Stock Analysis page.